Home > Insider Trading > Filing (0001104659-20-097717)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1641640	Nabriva Therapeutics Plc	NBRV	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1289946	Md Colin Broom	1000 Continental Drive Suite 600 King Of Prussia PA 19406		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2020-08-19	33,750	$0.00	260,000	No	4	M	Direct
Ordinary Shares	Disposition	2020-08-20	11,064	$0.65	248,936	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Share Units	Disposition	2020-08-19	33,750	$0.00	33,750	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units.
On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 67,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition.